Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors.

Hurtado, Felipe K; de Braud, Filippo; De Castro Carpeño, Javier; de Miguel Luken, Maria Jose; Wang, Ding; Scott, Jeffrey; Lau, Yvonne Y; McCulloch, Tracey; Mau-Sorensen, Morten

Hurtado, Felipe K; de Braud, Filippo; De Castro Carpeño, Javier; de Miguel Luken, Maria Jose; Wang, Ding; Scott, Jeffrey; Lau, Yvonne Y; McCulloch, Tracey; Mau-Sorensen, Morten.

Affiliation

Hurtado FK; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. felipe.kellermann_hurtado@novartis.com.
de Braud F; Fondazione IRCCS-Istituto Nazionale Dei Tumori, Milano, Italy.
De Castro Carpeño J; Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain.
de Miguel Luken MJ; CIOCC-Grupo Hospitalario de Madrid, Hosp. de Sanchinarro, Madrid, Spain.
Wang D; Henry Ford Cancer Institute, Detroit, MI, USA.
Scott J; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Lau YY; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
McCulloch T; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Mau-Sorensen M; Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

Cancer Chemother Pharmacol ; 87(4): 475-486, 2021 04.

Article in En | MEDLINE | ID: mdl-33394101

Subject(s)
Key words

ALK inhibitor; CYP2C9; CYP3A; Ceritinib; Drugdrug interaction; Midazolam; Pharmacokinetics; Warfarin

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfones / Cytochrome P-450 CYP3A / Cytochrome P-450 CYP2C9 / Anaplastic Lymphoma Kinase Type of study: Clinical_trials / Guideline Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2021 Document type: Article Affiliation country: Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google